Clinical Report: Worldwide Analysis of Cost-Effectiveness of CRT in Heart Failure
Overview
This systematic review evaluates the cost-effectiveness of cardiac resynchronization therapy (CRT) in heart failure patients. Findings indicate that CRT, particularly CRT-P, is a cost-effective treatment compared to optimal medical therapy alone, while CRT-D shows variable cost-effectiveness.
Background
Heart failure (HF) presents significant morbidity and mortality, imposing a heavy financial burden on healthcare systems globally. Cardiac resynchronization therapy (CRT) has emerged as an effective intervention for symptomatic heart failure patients with reduced ejection fraction, yet its cost implications require thorough evaluation. Understanding the cost-effectiveness of CRT is crucial for optimizing treatment strategies and resource allocation in heart failure management.
Data Highlights
Type of Therapy
ICER (€ per QALY)
CRT + OMT
€3,048 - €71,447
CRT-D vs CRT-P
€24,909 - €105,572
Key Findings
CRT + OMT is highly cost-effective across various healthcare settings.
ICERs for CRT + OMT range from €3,048 to €71,447 per QALY gained.
CRT-D shows more variability in cost-effectiveness, with ICERs between €24,909 and €105,572 per QALY gained.
CRT-P is recommended as a high-value therapy for symptomatic HFrEF patients.
CRT-D should be reserved for selected high-risk patients due to its variable cost-effectiveness.
Clinical Implications
Clinicians should consider CRT-P as a primary treatment option for patients with symptomatic HFrEF who do not respond adequately to optimal medical therapy. The variable cost-effectiveness of CRT-D suggests a more selective approach in its application, prioritizing high-risk patients.
Conclusion
The review underscores the cost-effectiveness of CRT, particularly CRT-P, in managing heart failure, highlighting the need for informed decision-making in treatment strategies.
Dr. Uprety discusses the current role of non-invasive testing for coronary artery disease, highlighting evidence-based diagnostic strategies and the appropriate use of imaging modalities to improve early detection, risk stratification, and clinical decision-making.
Damon B. Dixon, MD, at Phoenix Children’s Cardiology, is the author to this EndoText chapter. Dr. Dixon brings nationally recognized expertise in pediatric cardiovascular risk assessment and non?invasive vascular imaging.
